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Aggrecan and versican processing and bioactivity in cartilage 
repair
J.D. Sandy, A. Plaas, United States of America 
It is generally accepted that promoting the repair of damaged articular 
cartilage remains an important aspect of joint health maintenance. 
What is not so clear is the repair strategy which should be adopted1. 
Approaches range from insertion of non-biological materials such 
as metal, plastic or ceramics through to implantation of cartilage-
like tissue constructs, which may require specialized treatments 
to achieve integration with the recipient tissues. Other strategies 
attempt to optimize the endogenous capacity of the tissue for 
“self-repair”, by treatments which encourage invasion of reparative 
“stem” cells and re-construction of the tissue within the lesion site. 
The heterogeneity of the cartilage lesions, the diversity of the patient 
population and the attendant economic constraints provides a level 
of complexity which all most certainly precludes any single solution 
to this complex medical treatment issue. Nonetheless, reasonable 
success (as measured by quality of life tools) has been achieved in 
many instances and there are excellent prospects for future gains. 
From a biological viewpoint the effective repair (reconstruction, 
healing or reconstitution) of articular cartilage will require a highly 
sophisticated understanding of the tissue at the cell biological and 
matrix levels. For example, cartilage matrix contains major functional 
constituents, such as aggrecan and collagens, but the “real-
time” functioning of cartilage is the outcome of a highly complex 
interplay of these molecular building blocks with minor (maybe even 
undiscovered) matrix components, cell surface receptors, cytokine 
networks and signaling cascades. 
For this reason, basic studies2-4 which reveal novel mechanisms of 
cartilage and chondrocyte biology continue to offer the best chance 
for developing effective strategies for truly therapeutic repair. The 
purpose of this extended abstract is to review existing knowledge 
and add new data on roles for the matrix proteoglycans (the 
hyalectans, aggrecan and versican) in cartilage matrix homeostasis 
and repair. Products derived from proteolysis of these matrix 
proteoglycans can provide unique insight into the matrix processing 
events, which operate in degenerating as opposed to repairing 
cartilages. These “signals from the cartilage matrix” provide simple 
tools to determine with molecular markers whether a repair tissue 
is likely to both integrate into the host and maintain function for an 
extended period. 
The materials, methods, tissues, animal models, reagents and 
chemicals used in the experiments described have been published 
in a series of articles most recently summarized in an Editorial article 
for Osteoarthritis and Cartilage5. Discussion of work from other 
laboratories has been referenced and methodological details can be 
found within those articles.The antibodies used in these experiments 
UP EFUFDU TQFDJ¾D $UFSNJOBMMZ USVODBUFE BHHSFDBO GPSNT 	+4$%-4
JSCGVA, JSCVDI, JSCNIT, JSCTAS), aggrecan G3-bearing fragments 
(JSCDGH), ADAMTS-cleaved versican V0/V1(JSCDPE), ADAMTS5 
(JSCKNG ) and ADAMTS9 (JSCFDG), are each described by a unique 
3-residue sequence within the epitope. All can be obtained from Dr. 
John Sandy (Rush University, Chicago IL) on request (jsandy44@
HNBJMDPN
 BOEPS GSPN "G¾OJUZ #JPSFBHFOUT 	XXXCJPSFBHFOUT
com). 
Interpreting aggrecan fragment analysis in terms of the status of the 
cartilage requires a new understanding of the biological roles of the 
proteinases involved
Aggrecan metabolism (biosynthesis, secretion, deposition, 
proteolysis and removal from matrix by diffusional loss or cellular 
uptake) has been a major research area for many years and the 
major pathways are now well understood. Analysis of the chondroitin 
sulfate terminal disaccharide structures on human cartilage aggrecan 
can indicate for example, whether the aggrecan is derived from an 
immature (growing) cartilage or from a stable mature cartilage6. 
Such analysis might therefore also be applied to “repair” cartilages 
to determine whether they are suitably matched for integration into 
a mature recipient repair site. Proteolytic processing of the aggrecan 
core protein is now known to involve three major proteinase families 
(m-calpain-like3, MMP-like7 and ADAMTS-aggrecanases8,9), each of 
XIJDIGVM¾MMEJTDSFUFBOEJNQPSUBOUSPMFTJOBHHSFDBONFUBCPMJTN
It is the analysis of this discrete and highly regulated proteolytic 
processing which represents the focus of this abstract and which 
we propose can be used to determine whether the repair cartilage 
is in “steady state maintenance”, in “repair” or in “degradative 
imbalance”.
At the outset, it should be noted that this new data on aggrecanolysis 
challenges long-held and widely embraced assumptions and 
dogmas (see for example Ref. 10) about the “central role” of 
matrix metalloproteinases (MMPs) in cartilage matrix degradation. 
While excessive MMP activity may be responsible for initiating 
EFHSBEBUJPOPGTPNFDBSUJMBHFNBUSJYQSPUFJOTTVDIBTUIF¾CSJMMBS
collagens, there is increasing and persuasive evidence that MMP-
mediated aggrecanolysis is not destructive to cartilage but rather a 
reparative process. Such a role for MMPs in aggrecan metabolism 
is consistent with the now widely accepted role for MMPs in the 
homeostatic maintenance of matrix in a wide variety of tissues11. 
In addition, m-calpain-like activity alone appears to be responsible 
for generating the major C-terminally truncated forms of functional 
aggrecan in cartilage, consistent with a constructive role (rather 
than a destructive role) for m-calpains in cartilage. However, in 
marked contrast, it is one or more of the ADAMTS-aggrecanases 
(ADAMTS1,4,5,8,9,15) which is primarily, if not entirely responsible 
for destructive cleavage (and loss of function) of aggrecan in 
cartilage matrix.4 We suggest that understanding this emerging 
paradigm (viz: m-calpain and MMPs are constructive for cartilage 
aggrecan whereas ADAMTS-aggrecanases are destructive) is central 
to decision making in developing cartilage repair strategies.
m-Calpain-like proteinases generate aggrecan species for steady 
state maintenance of the tissue
Available data suggests that during biosynthesis/secretion of 
aggrecan the core protein is cleaved at two major sites by m-calpain-
like activity3,4,12. The intracellular location of this process12 
suggests that it probably occurs before glycosaminoglycans are 
added to the aggrecan core protein. One calpain site is at the junction 
of the CS-1 and CS-2 domains and cleavage here generates an 
abundant matrix product with the structure G1-G2-KS-CS1(globular 
domain 1-globular domain 2-keratan sulfate domain-chondroitin 
sulfate1-domain). This species is probably the major matrix form of 
cartilage aggrecan in mature human cartilages4 (described therein 
as band “a”) and, along with full-length aggrecan, it provides the 
tissue with its properties of water retention and effective resistance 
to compressive force. This calpain-generated species can be readily 
JEFOUJ¾FE CZ JUT DIBSBDUFSJTUJD NJHSBUJPO PO 4%41"(& BU BCPVU
250kDa and its reactivity with an antibody (JSCDLS) raised to the 
C-terminal neo-epitope sequence 1406GVEDLS14114. The other 
physiologically-important calpain cleavage site is at the junction of 
the G2 and KS-rich domains and cleavage here generates a group 
of products with the “double-globe” structure G1-G23,12. These 
products (and structurally similar variants) are the other major 
matrix forms of cartilage aggrecan in mature human12 and bovine3 
cartilages (described therein as bands “b”,”c” and “d”); these 
QSPEVDUTEPOPUCFBSTJHOJ¾DBOUBNPVOUTPG$4PS,4BOETPUIFJS
function must be other than simply matrix water retention. They do 
however represent structural components which bind to hyaluronan 
and which, most importantly, appear to be the primary substrates 
for further discrete and important proteolytic processing by MMPs 
(see below). These calpain-generated “double-globe” structures 
DBOCFJEFOUJ¾FECZUIFJSDIBSBDUFSJTUJDNJHSBUJPOPO4%41"(&	BU
120kDa-160kDa) and their reactivity with monoclonal Ab SK-283 
and polyclonal Abs (JSCGVA and Ref12), all of which recognize the 
C-terminal human neoepitope sequence 704VVPGVA709.
It follows from this data that only “repair” cartilages which 
contain both these calpain-generated aggrecan forms (G1-G2-KS-
CS1(JSCDLS-reactive), G1-G2 (JSCGVA-reactive)) can be considered to 
have acquired the suitable “steady-state” aggrecan matrix required 
for long-term tissue maintenance.This conclusion imposes quite 
distinct constraints of matrix composition on a robust cartilage repair 
construct or in vivo system. Conditions which promote aggrecan 
biosynthesis with concomitant calpain-mediated processing need to 
be established for effective repair. Moreover, since the conditions 
required for biosynthesis (ex vivo or in vivo) of these aggrecan forms 
have not yet been elucidated, further basic studies in this area are 
essential in the development of optimized cartilage repair strategies 
It also follows that the intuitive assumption by many, that “more 
aggrecan (CS) in a cartilage construct is better than less” will need 
UPCFSFFYBNJOFEBOEFYUFOEFEUPNPSFEF¾OFEBHHSFDBOBOBMZTFT
If the aggrecan generated in the construct, albeit abundant, does 
not “mimic” to some extent the aggrecan present in the recipient 
tissue, then it seems likely to elicit recipient responses which will 
compromise the biological success of the implant. In summary, it 
can be suggested that analyses of both the GAG composition (for 
appropriate CS and KS chain length and sulfation patterns) and the 
core protein composition of the repair cartilage (for appropriate C-
terminal truncations) will be needed to determine whether biological 
function and integration are likely to be successful in the long term.
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MMP-like proteinases generate aggrecan species for maintenance of 
the “mature” chondrocyte phenotype
Mature cartilages in many animal species contains an abundant 
aggrecan product, G1-VDIPEN3607. This hyaluronan (HA)-binding 
protein is most likely the product of MMPs (such as MMP-2 or MMP-
9) although it can also be formed in incubations of aggrecan with 
cathepsin B13 or ADAMTS-4 (aggrecanase-1)14. It has been suggested 
that the presence of this product in mature cartilages is evidence 
for MMP-mediated destruction of cartilage aggrecan15, however 
independent evidence from many laboratories (summarized in5) 
indicates that the G1-VDIPEN360 product is a normal intermediate, 
which is also an indicator of the “reparative” chondrocyte phenotype. 
Most persuasively, the inability of MMP-ablation to protect mice 
from experimental arthritis16 and the repeated observation that 
MMP ablation predisposes to precocious OA-like lesions17, invites 
and prompts the interpretation that MMP-mediated formation of G1-
VDIPEN360 is required for cartilage homeostatic maintenance.
Most interesting in this regard is the conclusion5 that the substrate 
for G1-VDIPEN360 formation in cartilage is not intact aggrecan but the 
calpain-generated G1-G2-GVA species described above. This follows 
GSPN UIF ¾OEJOH UIBU UIF DPNQMJNFOUBSZ QSPEVDU PG (7%*1&/
formation in vivo is a low-buoyant density fragment (361FFGVG-
positive) with a structure (SandyJD, unpublished) consistent with 
361FFGVG-G2-GVA709. It therefore appears that the formation of G1-
VDIPEN360 in cartilage and its immunolocalization (with antibody 
+4$7%*
 UP UIFQFSJDFMMVMBS TQBDF JT B TQFDJ¾D ²SFBEPVU³ PG OPO
destructive MMP-mediated aggrecanolysis.
5IFTF ¾OEJOHT TVHHFTU UIBU ²SFQBJS³ DBSUJMBHFT XIFUIFS CFJOH
prepared for tissue engineering and implantation purposes or 
generated in vivo following cell-based therapeutic approaches, 
should contain abundant G1-VDIPEN360 product. Indeed the 
presence of this product can be considered a positive indicator of 
a “reparative” chondrocyte phenotype, in distinct contrast to many 
publications which interpret this product as a marker of cartilage 
degradation (for example see 19). Just how the G1-VDIPEN360 
product “conditions” the chondrocyte for constructive repair is 
presently unknown, however it is possible that receptor-mediated 
VQUBLFPGUIJTQSPUFJOTQFDJ¾DBMMZTJHOBMTDFMMTUPEPXOSFHVMBUF
destructive cascades.
ADAMTS-aggrecanases are responsible for destructive aggrecanolysis 
in cartilage
There is now overwhelming evidence that ADAMTS-aggrecanases 
are primarily, and probably entirely, responsible for destructive 
aggrecanolysis in articular cartilages (see 4). The most compelling 
evidence is that ADAMTS-aggrecanase-generated fragments 
BDDVNVMBUFBCVOEBOUMZJOUIFTZOPWJBM¿VJETPGQBUJFOUTXJUIBSBOHF
of joint diseases21 and that ablation of ADAMTS5 in mice protects 
against cartilage loss in both OA-like and RA-like experimental 
models22,23. It should be emphasized that destructive aggrecanolysis 
	XIJDIDMFBSMZDPNQSPNJTFTUJTTVFGVODUJPO
JTDPO¾OFEUPUIBUUZQF
of proteolysis which results in loss of CS and KS-bearing aggrecan 
fragments,and therefore water, from the tissue. The ADAMTS-
generated aggrecan fragments which are most “diagnostic” of 
this kind of process are G1-NITEGE392 (detected with JSCNIT) 
and the complimentary product 393ARGSV-G2-KS-CS1(JSCDLS-
reactive) formed from the major matrix form of aggrecan, G1-G2-
KS-CS1(JSCDLS-reactive).Where ADAMTS-aggrecanase also cleaves 
intact (newly synthesized) aggrecan, products such as 393ARGSV-
G2-KS-CS1-TASELE1564 (detected with JSCTAS) and a “ladder” of 
G3-bearing products (detected with JSCDGH) are formed.
It follows that cartilage “repair” strategies which involve ex vivo 
tissue engineering, or cell-based therapies should be evaluated 
for the level of attendant destructive aggrecanolysis. A construct 
which contains high levels of G1-NITEGE392 and low levels of G1-
VDIPEN360 is less suitable than the inverse composition, since 
it is likely that it is undergoing high rates of destructive ADAMTS-
mediated aggrecanolysis and low rates of calpain-mediated 
assembly and MMP-mediated aggrecan matrix repair. Conversely, a 
tissue implant which is found in vivo to contain high levels of G1-
VDIPEN360 is most likely undergoing matrix assembly and should 
UIFSFGPSFIBWFBGBWPSBCMFSFQBJSQSP¾MF
ADAMTS-aggrecanases generate versican products in cartilage 
which are diagnostic of the destructive macrophage-like chondrocyte 
which emerges in early joint tissue destruction
Cleavage of versican (V0/V1) by ADAMTS-aggrecanases generates 
the HA-binding product G1-DPEAAE44124. This 70kDa product is 
SFBEJMZ JEFOUJ¾FE PO8FTUFSO BOBMZTJT BOE JNNVOPIJTUPDIFNJTUSZ
XJUIUIFOFPFQJUPQFBOUJCPEZ+4$%1&XIJDITQFDJ¾DBMMZEFUFDUTUIF
C-terminal sequence, DPEAAE441.. The abundance of this product 
has been found to be correlated with such diverse cellular processes 
BT ¿PXJOEVDFE OFPJOUJNBM SFHSFTTJPO JO WBTDVMBS HSBGUT UIF
formation and differentiation of endocardial cushion mesenchyme 
26, ovulation27 and glioma cell migration28. In recent studies with 
murine models of joint degradation and human clinical samples we 
have found (Plaas A and Sandy JD, unpublished) JSCDPE-positive 
cells in areas of active tissue remodeling such as at the meniscus/
joint capsule interface, the medial cartilage surface not covered by 
the meniscus and in developing osteophytes. Moreover in late stage 
OA, clonal cell groups, particularly near the surface of the cartilage 
BOEBEKBDFOUUP¾TTVSFTXFSF-09OVDMFBS+4$%1&BOETUBJOFE
abundantly for ADAMTS9 (with JSCFDG) and ADAMTS5 (with JSCKNG), 
the latter in complex with HA4. Thus, it appears that the presence of 
G1-DPEAAE441 is indicative of a population of progenitor (stem) cells 
with a degradative as opposed to cartilage-producing phenotype. It 
would follow that in cartilage repair strategies, where constructs are 
evaluated pre- or post-implantation or where endogenous repair 
is promoted, the analysis for G1-DPEAAE with antibody JSCDPE 
may provide important clues as to the status of the prominent cell 
population in terms of its reparative potential.
Repair of articular cartilage lesions presents multiple challenges 
due to the relative lack of inherent repair potential, problems of 
tissue integration and the biomechanically-demanding environment 
surrounding the repair site. Optimization of biological constructs for 
implantation and evaluation of repair tissues post-implantation or 
post lesion treatment requires evaluation of the suitability of the 
repair tissue for long-term survival. A major aspect of the “suitability 
test” is whether the repair tissue contains matrix components which 
reasonably duplicate the adjacent recipient tissue. Indeed, it can be 
argued that the matrix composition will largely determine whether 
the resident cells promote and maintain a repair response or revert 
to a destructive phenotype. 
In this paper we have described a series of novel antibodies which 
can be used to determine whether the aggrecan and versican 
metabolism of a neo-cartilage is adjusted for tissue repair. 
4QFDJ¾DBMMZ XF TVHHFTU UIBU UIF SFQBSBUJWF DBSUJMBHF NBUSJY XJMM
contain abundant aggrecan species reactive with the neo-epitope 
antibodies, JSCDLS, JSCGVA and JSCVDI, which detect products 
generated by m-calpain-like and MMP-like activities. In contrast, a 
matrix undergoing excessive degradation will be “diagnosed” by 
reactivity with JSCNIT and JSCDPE which detect products generated 
by ADAMTS-aggrecanase-mediated proteolysis of aggrecan and 
versican respectively. In summary, it is proposed that evaluation 
of repair cartilages with these reagents (in ELISA, Western analysis 
or immunohistochemistry) represents an important and highly 
instructive addition to other critical but more global analyses such 
as aggrecan concentration, collagen content and cross-linking, cell 
viability, biomechanical properties and tissue integration1. 
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